8-K/A: Breeze Holdings Faces Delisting Notice from OTCQX for Rights and Warrants

Breeze Holdings Acquisition Corp. received a notice from OTCQX Market regarding non-compliance with continued listing requirements related to its rights and warrants, with a deadline to cure the deficiency by June 13, 2025.

Summary

• Breeze Holdings Acquisition Corp. received a notice from OTCQX Market on March 17, 2025, indicating non-compliance with Section 2 of the Requirements for Continued Qualification of the OTCQX Rules for U.S. Companies.
• The deficiency pertains to the company's rights and warrants, trading under the tickers BRZHR and BRZHW, respectively, under Section 1.1(A) of the OTCQX Eligibility Criteria, related to penny stock exemption requirements.
• The company has 90 days, until June 13, 2025, to address the deficiency.
• Breeze Holdings is pursuing a business combination with YD Biopharma Limited, expected to close before the June 13, 2025 deadline.
• A condition of the business combination requires the combined company to be listed on the NASDAQ Capital Markets as of the closing date, unless otherwise waived.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delisting notice, but the planned business combination and potential NASDAQ listing offer a path to recovery.

Positives

• The company is pursuing a business combination with YD Biopharma Limited, which is expected to close before the June 13, 2025 deadline.
• The business combination includes a condition that the combined company be listed on the NASDAQ Capital Markets, which would resolve the OTCQX delisting issue.

Negatives

• Breeze Holdings received a notice of non-compliance from OTCQX, potentially leading to delisting of its rights and warrants.

Risks

• Failure to complete the business combination with YD Biopharma Limited before June 13, 2025, could result in the delisting of the company's rights and warrants from the OTCQX Market.
• The NASDAQ listing condition of the business combination could be waived, potentially leaving the company non-compliant with OTCQX rules.

Future Outlook

The company expects to close its business combination with YD Biopharma Limited prior to June 13, 2025, and as a condition of that business combination, unless otherwise waived, the combined company is required to be listed on the NASDAQ Capital Markets as of the closing date.

Management Comments

• J. Douglas Ramsey, Chief Executive Officer and Chief Financial Officer, signed the report on behalf of Breeze Holdings Acquisition Corp.

Industry Context

SPACs and small-cap companies often face challenges in maintaining listing compliance, particularly regarding penny stock rules and market capitalization requirements. This situation highlights the importance of timely business combinations and adherence to exchange regulations.

Comparison to Industry Standards

• Many SPACs face similar challenges with maintaining listing requirements, especially those trading on OTC markets.
• Companies like Digital World Acquisition Corp. (DWAC) have faced scrutiny and potential delisting issues related to their business combinations.
• The requirement to list on NASDAQ post-merger is a common strategy to ensure continued compliance and access to a broader investor base, similar to what companies like Faraday Future (FFIE) pursued after their SPAC merger.

Stakeholder Impact

• Shareholders of Breeze Holdings face the risk of delisting, which could negatively impact the value of their holdings.
• The successful completion of the business combination and NASDAQ listing is crucial for maintaining investor confidence and value.

Next Steps

• Cure the deficiency related to the rights and warrants to comply with OTCQX rules.
• Complete the business combination with YD Biopharma Limited.
• Secure a listing on the NASDAQ Capital Markets as a condition of the business combination.

Key Dates

Keywords

OTCQX, delisting, rights, warrants, BRZHR, BRZHW, Breeze Holdings, YD Biopharma, business combination, NASDAQ, compliance